Your browser doesn't support javascript.
loading
Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.
Parrish, C; Scott, G B; Migneco, G; Scott, K J; Steele, L P; Ilett, E; West, E J; Hall, K; Selby, P J; Buchanan, D; Varghese, A; Cragg, M S; Coffey, M; Hillmen, P; Melcher, A A; Errington-Mais, F.
Afiliación
  • Parrish C; Section of Oncology and Clinical Research, Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, St James's University Hospital, Leeds, UK.
  • Scott GB; Section of Oncology and Clinical Research, Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, St James's University Hospital, Leeds, UK.
  • Migneco G; Section of Oncology and Clinical Research, Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, St James's University Hospital, Leeds, UK.
  • Scott KJ; Section of Oncology and Clinical Research, Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, St James's University Hospital, Leeds, UK.
  • Steele LP; Section of Oncology and Clinical Research, Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, St James's University Hospital, Leeds, UK.
  • Ilett E; Section of Oncology and Clinical Research, Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, St James's University Hospital, Leeds, UK.
  • West EJ; Section of Oncology and Clinical Research, Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, St James's University Hospital, Leeds, UK.
  • Hall K; Section of Oncology and Clinical Research, Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, St James's University Hospital, Leeds, UK.
  • Selby PJ; Section of Oncology and Clinical Research, Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, St James's University Hospital, Leeds, UK.
  • Buchanan D; St James's University Hospital, Leeds, UK.
  • Varghese A; St James's University Hospital, Leeds, UK.
  • Cragg MS; Antibody and Vaccine Group, Cancer Sciences Unit, Southampton University, General Hospital, Southampton, UK.
  • Coffey M; Oncolytics Biotech Inc., Calgary, AB, Canada.
  • Hillmen P; Experimental Haematology, LICAP, University of Leeds, Leeds, UK.
  • Melcher AA; Section of Oncology and Clinical Research, Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, St James's University Hospital, Leeds, UK.
  • Errington-Mais F; Section of Oncology and Clinical Research, Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, St James's University Hospital, Leeds, UK.
Leukemia ; 29(9): 1799-810, 2015 Sep.
Article en En | MEDLINE | ID: mdl-25814029
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Orthoreovirus Mamífero 3 / Leucemia Linfocítica Crónica de Células B / Virus Oncolíticos / Rituximab / Citotoxicidad Celular Dependiente de Anticuerpos Tipo de estudio: Diagnostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Orthoreovirus Mamífero 3 / Leucemia Linfocítica Crónica de Células B / Virus Oncolíticos / Rituximab / Citotoxicidad Celular Dependiente de Anticuerpos Tipo de estudio: Diagnostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido